National Resource for Translational and Developmental Proteomics

国家转化和发育蛋白质组学资源

• 批准号: 9456539
• 负责人: NEIL L KELLEHER
• 金额: $ 0.78万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9456539
• 关键词: Acute Myelocytic Leukemia; Address; American; Area; Atherosclerosis; Automobile Driving; Back; Biological; Biomedical Technology; Cancer Patient; Cancer Survivor; Cardiovascular Diseases; Chicago; Chronic Lymphocytic Leukemia; Clinical Research; Collaborations; Computer software; Coronary heart disease; Country; Data Collection; Development; Diagnostic; Disease; Feedback; Fertility; Foundations; Fourier Transform; Fractionation; Funding; Generations; Goals; Graft Rejection; Histones; Housing; Information Technology; Institutes; International; Investments; Kidney Transplantation; Laboratories; Leadership; Letters; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Medical; Multiple Myeloma; Myocardial Infarction; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Nature; Oocytes; Organ Transplantation; Outcome; Paper; Patients; Performance; Positioning Attribute; Process; Protein Analysis; Proteins; Proteomics; Public Health; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Route; Sampling; Science; Secure; Services; TP53 gene; Technology; Time; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Validation; Vision; Woman; arm; base; biological research; biomarker discovery; cohort; exhaustion; fertility improvement; focus ultra; graft failure; improved; innovation; instrument; interest; liver transplantation; mouse model; new technology; next generation; novel; oncofertility; organ regeneration; outreach; pre-clinical research; public health relevance; research and development; technology development; training project; visiting scholar

 DESCRIPTION (PROVIDED BY APPLICANT): Here we propose a National Resouce for Translational and Developmental Proteomics (NRTDP). The science drivers are outlined in eight Driving Biomedical Projects that motivate the specific aims for four Technology Research and Development Projects. The impact of these combined activities, devoted to improving mass spectrometry-based proteomics using whole proteins as the primary unit of measurement, will be substantial. Integrated over all aspects of the resource (including biomedical application, technology development, dissemination and training), the projected impacts are aligned with both the spirit and the letter of a P41 Biomedical Technology Research Resource and the strategic goals of the NIH as a whole. Applying innovation to timely challenges in diverse areas of clinical and translational research will secure a leadership position for our nation in 'next-generation' proteomics technology. These technologies will serve driving projects and investigators to improve scientific understanding and diagnostics, ultimately improving the lives of cancer patients, recipients of kidney transplants, those afflicted with coronary heart disease, and to preserve fertility in women survivors of cancer (oncofertility). More specifically, we will focus ultra-high performance proteomics on sample sets deriving from research on various cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. In technology, we will accelerate the development of the leading platform for top-down proteomics, including two new Fourier-Transform instruments, new protein fractionation technologies, and the AUTOPILOT software suite to allow strategic objectives of biomedical projects to govern the most detailed aspects of data collection on a daily basis. A tailored workflow to enable pervasive and exhaustive analysis of core histones further augments the technology portfolio available in this deeply collaborative and deferential national resource housing a demonstrably high performing technical and administrative team. Good evidence of the team's ability to distill high-end research activities into robust servce lines is now visible. Interest in the laboratory as a hub for training has been robust (with over a dozen visiting scholars to date) and specific plans for expansion of these activities are included. Several routes of information and technology dissemeniation also described in the application. The administration and execution of all these activities is assured by a proven senior team operating the Proteomics Center of Excellence (PCE) at Northwestern, which also has very strong institutional backing to align proteomics ongoing in Chicago with national priorities of NIH-funded biological and translational research of the NIH. The advancement of general medical science envisioned here will be of interest to several institutes including NCI, NICHD, NIDDK, NIGMS, and NHLBI - all of which are heavily invested in proteomics research. Our team of senior researchers at the Proteomics Center of Excellence, along with over a dozen collaborating laboratories around the country, look forward to feedback regarding the proposed NRTDP.

 描述（由申请人提供）：在此，我们提出了国家转化和发育蛋白质组学资源 (NRTDP)，其中概述了八个驱动生物医学项目的科学驱动因素，这些项目推动了四个技术研究和开发项目的具体目标。致力于使用全蛋白质作为主要测量单位改进基于质谱的蛋白质组学的活动将在资源的各个方面（包括生物医学应用、技术开发、传播和培训），预计的影响与 P41 生物医学技术研究资源的精神和文字以及 NIH 的整体战略目标相一致，将创新应用于临床和转化不同领域的及时挑战。研究将确保我们国家在“下一代”蛋白质组学技术方面处于领先地位，这些技术将有助于推动项目和研究人员提高科学理解和诊断，最终改善癌症患者、肾移植受者和受苦者的生活。更具体地说，我们将重点关注从各种癌症（包括慢性淋巴细胞白血病、多发性骨髓瘤和急性骨髓瘤）研究中获得的样本集进行超高性能蛋白质组学。在技​​术方面，我们将加速开发领先的自上而下的蛋白质组学平台，包括两台新的傅里叶变换仪器、新的蛋白质分离技术和AUTOPILOT软件。套件允许生物医学项目的战略目标管理日常数据收集的最详细方面，定制的工作流程可以对核心组蛋白进行普遍和详尽的分析，进一步增强了这个深度协作和防御性国家资源住房中可用的技术组合。表现出色的技术和管理团队现在已经可见，该团队有能力将高端研究活动提炼成强大的服务线。 人们对该实验室作为培训中心的兴趣浓厚（迄今为止已有十多名访问学者），并且申请中还描述了扩展这些活动的几种信息和技术传播途径。所有这些活动均由西北大学蛋白质组学卓越中心 (PCE) 的一支久经考验的高级团队负责保证，该中心还拥有非常强大的机构支持，使芝加哥正在进行的蛋白质组学与 NIH 资助的生物和转化研究的国家优先事项保持一致。这里设想的普通医学科学的进步将引起包括 NCI、NICHD、NIDDK、NIGMS 和 NHLBI 在内的多个机构的兴趣，所有这些机构都在蛋白质组学研究方面投入了大量资金，以及我们蛋白质组学卓越中心的高级研究人员团队。与全国十多个合作实验室合作，期待收到有关拟议 NRTDP 的反馈。